1. Immunomodulatory kits generating leukaemia derived dendritic cells do not induce blast proliferation ex vivo: IPO-38 as a novel marker to quantify proliferating blasts in acute myeloid leukaemia.
- Author
-
Plett C, Klauer LK, Amberger DC, Ugur S, Rabe A, Fischer Z, Deen D, Hirn-Lopez A, Gunsilius C, Werner JO, Schmohl J, Krämer D, Rank A, Schmid C, and Schmetzer HM
- Subjects
- Biomarkers, Cell Proliferation, Dendritic Cells, Humans, Prostaglandins pharmacology, Prostaglandins E pharmacology, Leukemia, Myeloid, Acute
- Abstract
(Leukaemia derived) dendritic cells (DC, DC
leu ) are potent stimulators of anti-leukaemic activity in acute myeloid leukaemia (AML) and can be generated with immunomodulatory kits containing granulocyte-macrophage-colony-stimulating-factor (GM-CSF), prostaglandin-E1 (PGE1 ), prostaglandin-E2 (PGE2 ) and/or picibanil (OK-321). Potential adverse effects initiated through kits, especially the proliferation of blasts, must be ruled out to ensure treatment safety. We quantified proliferating blasts with the proliferation markers CD71 and Ki-67 and the novel proliferation marker IPO-38 before and after kit treatment ex vivo. IPO-38 hereby appeared to be the most sensitive marker; a combination with CD71 may add value when assessing proliferation kinetics. Kit treatment did not or only slightly (<5%) induce blast proliferation in most cases. An induction of blast proliferation was only found in single cases and could be compensated by DCleu -induced anti-leukaemic activity in most times. Overall, we appraise kit treatment to be safe in vivo., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Modiblast Pharma GmbH (Oberhaching, Germany) holds the European Patent 15,801,987.7–1118 and US Patent 15–517,627 “Use of immunomodulatory effective compositions for the immunotherapeutic treatment of patients suffering from myeloid leukemias”, in which Helga Maria Schmetzer is involved., (Copyright © 2022 Elsevier Inc. All rights reserved.)- Published
- 2022
- Full Text
- View/download PDF